financetom
Business
financetom
/
Business
/
Macy's Says Employee Hid up to $154 Million in Expenses, Delays Fiscal Q3 Results, Reports Fiscal Q3 Preliminary Revenue Down
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Macy's Says Employee Hid up to $154 Million in Expenses, Delays Fiscal Q3 Results, Reports Fiscal Q3 Preliminary Revenue Down
Nov 25, 2024 5:03 AM

07:43 AM EST, 11/25/2024 (MT Newswires) -- Macy's (M) said in a preliminary statement on its fiscal Q3 results that a former employee attempted to hide about $132 million to $154 million in delivery expenses from fiscal Q4 2021 through the most recent quarter ended Nov. 2.

The company said there was no suggestion that "the erroneous accounting" impacted the company's vendor payments, but that it is delaying its earnings release and conference until as late as Dec. 11 to allow for an independent audit of the discrepancies.

The company also said preliminary revenue for the fiscal quarter ended Nov. 2 was $4.74 billion, down 2.4% from a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oxford Lane Capital Commences Public Offering of Notes
Oxford Lane Capital Commences Public Offering of Notes
Jun 26, 2024
04:32 PM EDT, 06/26/2024 (MT Newswires) -- Oxford Lane Capital ( OXLC ) said Wednesday it has started a registered public offering of notes. The price and terms of the notes will be negotiated with underwriters, who will have a 30-day option to purchase additional notes, according to the company. Oxford Lane plans to use proceeds from the offering to...
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing
Jun 26, 2024
04:34 PM EDT, 06/26/2024 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on June 24, 2024, sold 8,301 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,917,475. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 80,941 shares of the company, with 80,534 shares held directly and 407 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1178670/000173527624000068/xslF345X03/edgardoc.xml...
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing
Jun 26, 2024
04:33 PM EDT, 06/26/2024 (MT Newswires) -- Pushkal Garg, Chief Medical Officer and Executive Vice President of Development and Medical Affairs, on June 24, 2024, sold 2,103 shares in Alnylam Pharmaceuticals ( ALNY ) for $485,773. Following the Form 4 filing with the SEC, Garg has control over a total of 16,290 shares of the company, with 15,609 shares held...
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing
Jun 26, 2024
04:32 PM EDT, 06/26/2024 (MT Newswires) -- David E I Pyott, Director, on June 24, 2024, sold 32,450 shares in Alnylam Pharmaceuticals ( ALNY ) for $7,161,360. Following the Form 4 filing with the SEC, Pyott has control over a total of 28,036 shares of the company, with 136 shares held directly and 27,900 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1178670/000173527624000070/xslF345X03/edgardoc.xml Price:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved